Biotechnology company Aptevo Therapeutics Inc. said on Monday it had raised approximately $4.5 million through a mix of warrant exercises and new equity financing.
The proceeds will be used to strengthen the company’s financial position and support ongoing operations, including research and development activities, according to a regulatory filing. Aptevo did not disclose the specific terms of the equity issuance or the warrant exercise in its announcement.
The financing follows recent strategic shifts at Aptevo, which has focused on advancing its pipeline of antibody-based therapies. The company has previously relied on equity and debt markets to fund its operations amid volatile biotech funding conditions.
Aptevo’s shares were trading lower on Monday, reflecting broader sector pressures in biotechnology stocks. The company’s market capitalization remains modest, and liquidity constraints have been a recurring challenge in recent quarters.
Further details on the financing structure and allocation of funds are expected to be provided in upcoming filings with the U.S. Securities and Exchange Commission.
